News coverage about Horizon Pharma (NASDAQ:HZNP) has trended somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Horizon Pharma earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.1906457019727 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media headlines that may have effected Accern Sentiment’s analysis:

Shares of Horizon Pharma (NASDAQ:HZNP) traded up $0.38 during trading hours on Tuesday, reaching $14.44. 1,801,405 shares of the company were exchanged, compared to its average volume of 3,442,341. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64. The firm has a market capitalization of $2,380.00, a P/E ratio of 10.38, a P/E/G ratio of 1.21 and a beta of 1.31. Horizon Pharma has a 1 year low of $9.45 and a 1 year high of $20.25.

Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 EPS for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.04. The firm had revenue of $271.60 million during the quarter, compared to the consensus estimate of $259.74 million. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. The firm’s revenue was up 30.1% compared to the same quarter last year. During the same quarter last year, the firm earned $0.70 earnings per share. analysts predict that Horizon Pharma will post 0.72 earnings per share for the current fiscal year.

A number of equities analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $17.00 price target (up previously from $13.00) on shares of Horizon Pharma in a report on Wednesday, August 9th. Zacks Investment Research raised Horizon Pharma from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Piper Jaffray Companies set a $18.00 price target on Horizon Pharma and gave the stock a “buy” rating in a report on Monday, August 7th. BMO Capital Markets reissued an “outperform” rating and set a $18.00 price target (up previously from $17.00) on shares of Horizon Pharma in a report on Thursday, August 10th. Finally, Goldman Sachs Group assumed coverage on Horizon Pharma in a report on Thursday, September 28th. They set a “buy” rating and a $16.00 price target on the stock. One analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $18.75.

WARNING: This news story was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://theolympiareport.com/2017/12/05/horizon-pharma-hznp-receives-daily-coverage-optimism-score-of-0-19.html.

About Horizon Pharma

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Insider Buying and Selling by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.